Obstructive sleep apnea is a sleep-related breathing disorder in which recurrent upper-airway collapse during sleep causes intermittent airflow reduction or cessation, fragmented sleep, and cardiometabolic risk.
Q1 2026 sleep medicine trends include broader use of AI, expanding obstructive sleep apnea and narcolepsy treatments, and policy changes affecting reimbursement and access.
A study of over 600,000 patients reveals GLP-1 drugs may reduce addiction across multiple substances, with 50% fewer substance-related deaths and significant reductions in overdoses and hospitalizations. The drugs work by dampening dopamine signaling in brain reward centers. Researchers are exploring broader applications for these medications beyond diabetes and obesity treatment.
Eli Lilly's orforglipron demonstrated superior A1C reduction and weight loss compared to oral semaglutide in the ACHIEVE-3 trial, with regulatory submissions filed in over 40 countries and a potential US decision expected in Q2 2026.
Children with obstructive sleep apnea face nearly twice the risk of contracting influenza or COVID-19 compared to controls, with increased vulnerability persisting even after adenotonsillectomy, according to a five-year study of over 1 million children.
Eli Lilly is developing multiple next-generation obesity treatments, including oral GLP-1 drug orforglipron expected to launch in Q2 2026, as competition intensifies in a market projected to reach $95 billion by 2030.
UK and Brazil issue warnings about possible pancreatitis link to GLP-1 weight-loss drugs, while WADA monitors their use in Olympic athletes amid concerns about muscle loss and performance effects.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07603583 |
Assessment of Heart Rate Variability for Predicting Obstructive Sleep Apnea in Patients With Hypertension |
RECRUITING | |
| NCT07594288 |
Baveno Classification Versus Polysomnography in Obstructive Sleep Apnea |
COMPLETED | |
| NCT07581964 |
Effect of Sleep Apnea on Pain After Dental Treatment |
COMPLETED | |
| NCT07577661 |
Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07570953 |
A Study Of Synthetic THC And Sleep |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07545421 |
Residual Sleepiness and Accident Risk in Treated Obstructive Sleep Apnea |
NOT_YET_RECRUITING | NA |
| NCT07539870 |
Orofacial Myofunctional Therapy and Positive Airway Pressure-CPAP Trial for Mild-to-Moderate Obstructive Sleep Apnea |
NOT_YET_RECRUITING | NA |
| NCT07530523 |
KPAP vs EPR for Efficacy |
NOT_YET_RECRUITING | NA |
| NCT07530510 |
KPAP vs EPR for Comfort |
NOT_YET_RECRUITING | NA |
| NCT07521319 |
Wearable Voice-Guided BBTi for Comorbid Insomnia and Sleep Apnea (COMISA) |
NOT_YET_RECRUITING | NA |
